Safety Evaluation and Toxicology Studies and Related Services for Drug Development
Active Master IDIQ Awarded
- Federal agency
-
National Center for Advancing Translational Sciences
- Awardees
- 5
- Task orders
- 3
- Obligated
- $549,006
Vehicle facts
- Opportunity
-
- Safety Evaluation and Toxicology Studies and Related Services for Drug Development Pre-Solicitation · 75N95023R00029 · Posted May 11, 2023
- Agency
-
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- Combined task order value
- $549,006 Current and potential, with all options
- Last date to order 39% complete
- Shared ceiling 1% used
- $48,622,546.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health under the Department of Health and Human Services, established this Master IDIQ on June 20, 2024, to procure safety evaluation and toxicology studies and related services for drug development, with ordering authority extending through June 19, 2030.
The vehicle remains active with nearly four years of ordering authority remaining. Only three task orders have been awarded since vehicle inception, all within the first quarter following establishment (June through September 2024), generating a combined potential value of $514 thousand, fully obligated. This sparse ordering activity reflects early-stage vehicle maturation or limited near-term customer demand. The most substantive order, awarded September 18, 2024, to IIT Research Institute for $512 thousand, funds safety evaluation and toxicology studies on a first-in-class small molecule candidate (NCGC72, a CD206 agonist) for immunologically cold solid organ cancers, with performance due December 31, 2025. The two other orders, each valued at $1 thousand and awarded to Mriglobal and Charles River Laboratories in June and August 2024 respectively, supported kick-off meetings and program administration.
All task orders are unrestricted, full-and-open competition awards. The vehicle serves a single customer: NCATS itself. The awardee base consists of three distinct primes; no dominant contractor has emerged. IIT Research Institute holds the largest single award but accounts for only about 99.5 percent of obligated value across a single order. Work is classified under NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences), with a 1,000-employee size standard. Pursuit considerations include the vehicle's full-and-open structure, the nascent order flow, the specialized nature of preclinical toxicology and safety evaluation services, and the vehicle's potential value ceiling of $48.6 million, which substantially exceeds current obligations and signals capacity for significant future orders if NCATS prioritizes this vehicle for drug development pipeline advancement.
IDV awards
Latest task orders
| Task order | Awardee | Awarding agency | Obligated | Last action |
|---|---|---|---|---|
| First-in-class small molecule candidate NCGC72 (CD206 agonist) for… | IIT Research Institute | NIDA | $547,006 | |
| Kick-off meeting for safety evaluation and toxicology studies and related… | Charles River Laboratories, Inc. | NIDA | $1,000 | |
| Kick-off meeting for safety evaluation and toxicology studies and related… | Mriglobal | NIDA | $1,000 |
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | IIT Research Institute | $547,006 | 100% |
| 2 | Mriglobal | $1,000 | <1% |
| 3 | Charles River Laboratories, Inc. | $1,000 | <1% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $549,006 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2026 | $34,740 |
| FY2024 | $514,266 |
Quick answers
What is the Safety Evaluation and Toxicology Studies and Related Services for Drug Development contract vehicle?
Safety Evaluation and Toxicology Studies and Related Services for Drug Development is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Center for Advancing Translational Sciences (National Institutes of Health), awarded on June 20, 2024.
Which companies hold Safety Evaluation and Toxicology Studies and Related Services for Drug Development?
5 companies hold Safety Evaluation and Toxicology Studies and Related Services for Drug Development's IDV awards, one each. The latest went to Charles River Laboratories, Inc. on August 12, 2024. The awardees whose task orders obligated the most are IIT Research Institute, Mriglobal and Charles River Laboratories, Inc.
How much has been spent through Safety Evaluation and Toxicology Studies and Related Services for Drug Development?
3 task orders have been placed under Safety Evaluation and Toxicology Studies and Related Services for Drug Development, obligating $549,006.
What is the shared ceiling of Safety Evaluation and Toxicology Studies and Related Services for Drug Development?
Safety Evaluation and Toxicology Studies and Related Services for Drug Development's shared ceiling is $48,622,546; its task orders have used 1% of it.
Which agencies use Safety Evaluation and Toxicology Studies and Related Services for Drug Development the most?
The departments whose task orders under Safety Evaluation and Toxicology Studies and Related Services for Drug Development obligated the most are Department of Health and Human Services ($549,006).
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle